Market Access and Reimbursement Insights

Chronic Obstructive Pulmonary Disease (COPD) – Market Access and Reimbursement Insights Report – 2026

Updated Date: 20 Nov 2026 Delivery Time: 48 to 72 hours Request Free Sample

Chronic Obstructive Pulmonary Disease (COPD) Market Access and Reimbursement Insights

Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Access and Reimbursement Insights Report – 2026″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. As the third leading cause of death worldwide, its prevalence and fatality rates are projected to rise in the coming decades. The disease is characterized by chronic inflammation that causes structural alterations and constriction in the smaller air passages. This inflammatory process also drives lung tissue damage, resulting in the detachment of alveoli from smaller airways and a decrease in lung elasticity, which ultimately reduces the airways’ ability to remain open during exhalation. To assess the extent of airflow restriction, spirometry serves as the most accessible and dependable measure of lung function, with diagnosis confirmed by a post-bronchodilator FEV1/FVC ratio of less than 0.70. The clinical impact of COPD on an individual is determined not only by the degree of airflow limitation but also by the severity of associated symptoms and the frequency of exacerbations. Because an imperfect correlation exists between the degree of airflow limitation and patient symptoms, modern staging acts as a practical framework that combines spirometric grading with symptom burden and exacerbation risk to guide the initial management plan.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

  • PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

  • Market access and reimbursement for current therapies
    • Coverage on plans
    • Market access restrictions
    • Rebates and contracting
    • Factors influencing formulary access
    • HEOR requirements and influence, etc.
  • Expected market access and reimbursement for key emerging therapies
    • Level of awareness
    • Anticipated coverage on plans
    • Factors that would improve market access
    • Pricing, etc.
  • Impact on brand use
    • Key factors driving and limiting brand use
    • Best and worst performers on market access, etc.
  • Evolving environment
    • Payer expectations from emerging therapies
    • New policies and their expected impact, etc.
    • Advise to drug manufacturers and developers

 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

A look inside the report

Blurred previews. Click any figure to request it.

No snapshots available.

See the real pages first. Request a free sample of this report. Get the Free Sample

Before you buy

  • That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.

Select file type

Choose the file type you want to purchase or request.

No file type found.

Markets

Select markets to include.

  • Secure checkout
  • 48 to 72 hours

Recently viewed reports

No recently viewed reports yet. Reports you open will appear here.
Need help or guidance?

Not sure which report fits your question? Our team will point you to the right one.

Custom research

Can't find the exact report you need?

Tell us what you are looking for and we will tailor the research to your indication, markets and questions.

Build your request

    I need for covering .

    Prefer to talk it through? Email clientsupport@thelansis.com

    Thanks, , we have your request

    You asked for for covering . We will reply to .


      We use your details only to send what you asked for. Read our privacy policy.

      Contact Us

      Fill in your details and our expert consultants will get in touch with you.

        * Required fields are marked

          Request Bundle Discount

          Get exclusive pricing for report bundles.

          *
          Required fields are marked












          Your information is secure and confidential.

            Request Epilansis Demo

            See how Epilansis can support your business.

            *
            Required fields are marked












            Your information is secure and confidential.

            Request your free sample

            Tell us where to send it. It takes under a minute.